Today, we are excited to announce our investment in Alpha-9 Oncology’s $175M Series C funding round. Radiopharmaceuticals have the potential to harness the power of targeted therapeutics combined with the effectiveness of radiation as an anti-cancer therapy. With a strong team, diversified toolbox of building blocks and isotopes, and robust discovery capabilities, Alpha-9 is working to create radiopharmaceuticals that are highly optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. We believe Alpha-9’s pipeline has the potential to substantially advance cancer treatment, particularly for patients with high unmet needs.

Dr. David Hirsch, Alpha-9’s CEO, leads a deeply experienced team of drug developers dedicated to building a differentiated portfolio of what we believe can be best-in-class and first-in-class drugs—advancing multiple programs in parallel. 

With this financing, Alpha-9 Oncology aims to support further clinical studies and advance their pipeline of radiopharmaceuticals. Our Health Assurance thesis is aligned with Alpha-9’s mission to develop life-saving, highly efficacious, and safe drugs for cancer patients, and we are grateful to have the opportunity to partner with Alpha-9.